Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2003 1
2004 3
2005 1
2006 2
2007 1
2008 2
2009 1
2010 1
2011 2
2012 1
2013 2
2014 2
2015 1
2016 1
2017 4
2018 6
2019 4
2020 8
2021 4
2022 6
2023 4
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

55 results

Results by year

Filters applied: . Clear all
Page 1
Copy number architectures define treatment-mediated selection of lethal prostate cancer clones.
Hasan AMM, Cremaschi P, Wetterskog D, Jayaram A, Wong SQ, Williams S, Pasam A, Trigos A, Trujillo B, Grist E, Friedrich S, Vainauskas O, Parry M, Ismail M, Devlies W, Wingate A, Linch M, Naceur-Lombardelli C; PEACE consortium; Swanton C, Jamal-Hanjani M, Lise S, Sandhu S, Attard G. Hasan AMM, et al. Nat Commun. 2023 Aug 10;14(1):4823. doi: 10.1038/s41467-023-40315-9. Nat Commun. 2023. PMID: 37563129 Free PMC article.
PreCancer Atlas: Present and Future.
Srivastava S, Wagner PD, Hughes SK, Ghosh S. Srivastava S, et al. Among authors: ghosh s. Cancer Prev Res (Phila). 2023 Jul 5;16(7):379-384. doi: 10.1158/1940-6207.CAPR-22-0435. Cancer Prev Res (Phila). 2023. PMID: 37403657 Review.
Non-Small Cell Lung Cancer (NSCLC) in Young Adults, Age < 50, Is Associated with Late Stage at Presentation and a Very Poor Prognosis in Patients That Do Not Have a Targeted Therapy Option: A Real-World Study.
Hughes DJ, Kapiris M, Podvez Nevajda A, McGrath H, Stavraka C, Ahmad S, Taylor B, Cook GJR, Ghosh S, Josephs D, Pintus E, Gennatas S, Bille A, Ryanna K, Santis G, Montes A, Van Hemelrijck M, Karapanagiotou E, Smith D, Spicer J, Georgiou A. Hughes DJ, et al. Among authors: ghosh s. Cancers (Basel). 2022 Dec 9;14(24):6056. doi: 10.3390/cancers14246056. Cancers (Basel). 2022. PMID: 36551542 Free PMC article.
Folate receptor alpha in ovarian cancer tissue and patient serum is associated with disease burden and treatment outcomes.
Bax HJ, Chauhan J, Stavraka C, Santaolalla A, Osborn G, Khiabany A, Grandits M, López-Abente J, Palhares LCGF, Chan Wah Hak C, Robinson A, Pope A, Woodman N, Naceur-Lombardelli C, Malas S, Coumbe JEM, Nakamura M, Laddach R, Mele S, Crescioli S, Black AM, Lombardi S, Canevari S, Figini M, Sayasneh A, Tsoka S, FitzGerald K, Gillett C, Pinder S, Van Hemelrijck M, Kristeleit R, Ghosh S, Montes A, Spicer J, Karagiannis SN, Josephs DH. Bax HJ, et al. Among authors: ghosh s. Br J Cancer. 2023 Jan;128(2):342-353. doi: 10.1038/s41416-022-02031-x. Epub 2022 Nov 19. Br J Cancer. 2023. PMID: 36402875 Free PMC article.
Efficacy and Safety of Brigatinib Compared With Crizotinib in Asian vs. Non-Asian Patients With Locally Advanced or Metastatic ALK-Inhibitor-Naive ALK+ Non-Small Cell Lung Cancer: Final Results From the Phase III ALTA-1L Study.
Ahn MJ, Kim HR, Yang JCH, Han JY, Li JY, Hochmair MJ, Chang GC, Delmonte A, Lee KH, Campelo RG, Gridelli C, Spira AI, Califano R, Griesinger F, Ghosh S, Felip E, Kim DW, Liu Y, Zhang P, Popat S, Camidge DR. Ahn MJ, et al. Among authors: ghosh s. Clin Lung Cancer. 2022 Dec;23(8):720-730. doi: 10.1016/j.cllc.2022.07.008. Epub 2022 Jul 21. Clin Lung Cancer. 2022. PMID: 36038416 Free article. Clinical Trial.
Allele-informed copy number evaluation of plasma DNA samples from metastatic prostate cancer patients: the PCF_SELECT consortium assay.
Orlando F, Romanel A, Trujillo B, Sigouros M, Wetterskog D, Quaini O, Leone G, Xiang JZ, Wingate A, Tagawa S, Jayaram A, Linch M; PEACE Consortium; Jamal-Hanjani M, Swanton C, Rubin MA, Wyatt AW, Beltran H, Attard G, Demichelis F. Orlando F, et al. NAR Cancer. 2022 May 27;4(2):zcac016. doi: 10.1093/narcan/zcac016. eCollection 2022 Jun. NAR Cancer. 2022. PMID: 35664542 Free PMC article.
Determinants of anti-PD-1 response and resistance in clear cell renal cell carcinoma.
Au L, Hatipoglu E, Robert de Massy M, Litchfield K, Beattie G, Rowan A, Schnidrig D, Thompson R, Byrne F, Horswell S, Fotiadis N, Hazell S, Nicol D, Shepherd STC, Fendler A, Mason R, Del Rosario L, Edmonds K, Lingard K, Sarker S, Mangwende M, Carlyle E, Attig J, Joshi K, Uddin I, Becker PD, Sunderland MW, Akarca A, Puccio I, Yang WW, Lund T, Dhillon K, Vasquez MD, Ghorani E, Xu H, Spencer C, López JI, Green A, Mahadeva U, Borg E, Mitchison M, Moore DA, Proctor I, Falzon M, Pickering L, Furness AJS, Reading JL, Salgado R, Marafioti T, Jamal-Hanjani M; PEACE Consortium; Kassiotis G, Chain B, Larkin J, Swanton C, Quezada SA, Turajlic S; TRACERx Renal Consortium. Au L, et al. Cancer Cell. 2021 Nov 8;39(11):1497-1518.e11. doi: 10.1016/j.ccell.2021.10.001. Epub 2021 Oct 28. Cancer Cell. 2021. PMID: 34715028 Free PMC article.
55 results